title: Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects.
abstract: In this study, we reported a simple polydopamine (pD)-based surface modification method to prepare novel nanoparticle-aptamer bioconjugates (Apt-pD-DTX/NPs) for in vivo tumor targeting and enhanced therapeutic effects of breast cancer. With simple preparation procedures, the new functionalized Apt-pD-DTX/NPs could maximumly increase the local effective drug concentration on tumor sites, achieving enhanced treatment effectiveness and minimizing side effects. The dopamine polymerization and aptamer conjugation barely changed the characters of NPs. Both in vitro cell experiments (i.e. endocytosis of fluorescent NPs, in vitro cellular targeting and cytotoxicity assays) and in vivo animal studies (i.e. in vivo imaging, biodistribution and antitumor effects of NPs) demonstrated that the Apt-pD-DTX/NPs could achieve significantly high targeting efficiency and enhanced therapeutic effects compared with clinical Taxotere(®) and NPs without functional modification. Above all, the Apt-pD-DTX/NPs showed great potential as a promising nanoformulation for in vivo breast cancer therapy and the construction of pD-modified NP-aptamer bioconjugates could be of great value in medical use.
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;; 2. School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China.; 3. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
authors.forename: Wei
authors.initials: W
authors.lastname: Tao
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;; 2. School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China.
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Zeng
authors.affiliation: 4. Department of Biomedical Engineering, School of Engineering, Sun Yat-sen University, Guangzhou 510006, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wu
authors.affiliation: 3. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
authors.forename: Xi
authors.initials: X
authors.lastname: Zhu
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;
authors.forename: Xinghua
authors.initials: X
authors.lastname: Yu
authors.affiliation: 5. Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
authors.forename: Xudong
authors.initials: X
authors.lastname: Zhang
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;; 2. School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China.
authors.forename: Jinxie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;; 2. School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China.
authors.forename: Gan
authors.initials: G
authors.lastname: Liu
authors.affiliation: 1. The Shenzhen Key Lab of Gene and Antibody Therapy, and Division of Life and Health Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China;; 2. School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China.
authors.forename: Lin
authors.initials: L
authors.lastname: Mei
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D007211:Indoles / Q000378:metabolism*; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D011108:Polymers / Q000378:metabolism*; D017207:Rats, Sprague-Dawley; D013499:Surface Properties; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D052157:Aptamers, Nucleotide; D004337:Drug Carriers; D007211:Indoles; D011108:Polymers; C568283:polydopamine
keywords: Aptamer; Cancer targeting; Dopamine; Enhanced therapeutic effects.; Nanomedicine